Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine

被引：48

作者：

Bartosik-Psujek, H ^{[1
]}

Belniak, E ^{[1
]}

Mitosek-Szewczyk, K ^{[1
]}

Dobosz, B ^{[1
]}

Stelmasiak, Z ^{[1
]}

机构：

[1] Med Univ, Dept Neurol, PL-20090 Lublin, Poland

来源：

ACTA NEUROLOGICA SCANDINAVICA | 2004年 / 109卷 / 06期

关键词：

multiple sclerosis; interleukin-8; RANTES; cladribine; multiple sclerosis therapy;

D O I：

10.1111/j.1600-0404.2004.00259.x

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Objective - Chemokines are involved in the pathogenesis of multiple sclerosis. The aim of the study was to evaluate the effects of immunosuppressive therapy on production of two proinflammatory chemokines - interleukin-8 (IL-8) and RANTES (regulated on activation, normal T cell expressed and secreted). Materials and methods - Twenty-five patients with relapsing-remitting multiple sclerosis were treated with 2-chlorodeoxyadenosine (Cladribine), administered subcutaneously in 6 cycles repeated every 5 weeks. IL-8 and RANTES levels were measured by the enzyme-linked immunoassay (ELISA) method in serum and cerebrospinal fluid (CSF) before and after treatment. Results - After Cladribine treatment the levels of IL-8 decreased significantly in CSF only, whereas the RANTES levels decreased significantly both in CSF and serum. Conclusion - Our results suggest that Cladribine therapy might modify the circulating level of RANTES.

引用

页码：390 / 392

页数：3

共 9 条

[1] Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s [J].

Bonecchi, R ;

Bianchi, G ;

Bordignon, PP ;

D'Ambrosio, D ;

Lang, R ;

Borsatti, A ;

Sozzani, S ;

Allavena, P ;

Gray, PA ;

Mantovani, A ;

Sinigaglia, F .

JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (01) :129-134

[2] The clinical pharmacokinetics of cladribine [J].

Liliemark, J .

CLINICAL PHARMACOKINETICS, 1997, 32 (02) :120-131

[3] Chemokines - Chemotactic cytokines that mediate inflammation [J].

Luster, AD .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (07) :436-445

[4] Expression of chemokine receptors in the different clinical forms of multiple sclerosis [J].

Martínez-Cáceres, EM ;

Espejo, C ;

Brieva, L ;

Pericot, I ;

Tintoré, M ;

Sáez-Torres, I ;

Montalban, X .

MULTIPLE SCLEROSIS, 2002, 8 (05) :390-395

[5]

Michalowska-Wender G, 1999, Neurol Neurochir Pol, V33, P749

[6] Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis [J].

Rudick, RA ;

Cookfair, DL ;

Simonian, NA ;

Ransohoff, RM ;

Richert, JR ;

Jacobs, LD ;

Herndon, RM ;

Salazar, AM ;

Fischer, JS ;

Granger, CV ;

Goodkin, DE ;

Simon, JH ;

Bartoszak, DM ;

Bourdette, DN ;

Braiman, J ;

Brownscheidle, CM ;

Coats, ME ;

Cohan, SL ;

Dougherty, DS ;

Kinkel, RP ;

Mass, MK ;

Munchsauer, FE ;

O'Reilly, K ;

Priore, RL ;

Pullicino, PM ;

Scherokman, BJ ;

Wende, K ;

Weinstock-Guttman, B ;

Whitham, RH .

JOURNAL OF NEUROIMMUNOLOGY, 1999, 93 (1-2) :8-14

[7] Differential release of β-chemokines in serum and CSF of patients with relapsing-remitting multiple sclerosis [J].

Sindern, E ;

Niederkinkhaus, Y ;

Henschel, M ;

Ossege, LM ;

Patzold, T ;

Malin, JP .

ACTA NEUROLOGICA SCANDINAVICA, 2001, 104 (02) :88-91

[8] Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients [J].

Sorensen, TL ;

Tani, M ;

Jensen, J ;

Pierce, V ;

Lucchinetti, C ;

Folcik, VA ;

Qin, SX ;

Rottman, J ;

Sellebjerg, F ;

Strieter, RM ;

Frederiksen, JL ;

Ransohoff, RM .

JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (06) :807-815

[9] Chemokines and chemokine receptors in the pathogenesis of multiple sclerosis [J].

Zhang, GX ;

Baker, CM ;

Kolson, DL ;

Rostami, AM .

MULTIPLE SCLEROSIS JOURNAL, 2000, 6 (01) :3-13

← 1 →